First treatment of a child suffering from severe ischemic cardiomyopathy with G-CSF and sitagliptin.
Department of Internal Medicine III, Cardiology and Angiology, Medical University Innsbruck, Innsbruck, Austria. Electronic address: Marc-Michael.Zaruba@i-med.ac.at.
Marc-Michael
MM
Zaruba
Lucia
L
Hiergeist
Andra
A
Mechea
Rainer
R
Kozlik-Feldmann
Daniel
D
Theisen
Heinrich
H
Netz
Wolfgang-Michael
WM
Franz
D009202:Cardiomyopathies / Q000188:drug therapy*; D003131:Combined Modality Therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; D016179:Granulocyte Colony-Stimulating Factor; D000068900:Sitagliptin Phosphate
CXCR4; Dual stem cell therapy; Myocardial regeneration; SDF-1; Stem cells